-
1.发明授权ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) 有权ZAP-70表达作为慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL / SLL）的标记物公开(公告)号：US07329502B2
公开(公告)日：2008-02-12
申请号：US10309548
申请日：2002-12-03
IPC分类号： G01N33/574
CPC分类号： G01N33/57426 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA mRNA or protein.
摘要翻译： 已经令人惊奇地发现，在蛋白质和mRNA水平上的ZAP-70表达指示CLL / SLL患者的临床亚组。 特别地，高ZAP-70表达指示Ig-未突变的CLL / SLL。 提供了通过确定受试者是否过表达ZAP-70 mRNA mRNA或蛋白质来区分CLL / SLL的临床亚组的方法。
-
2.发明申请ZAP-70 EXPRESSION AS A MARKER FOR CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) 有权ZAP-70表达作为慢性淋巴细胞淋巴瘤/小淋巴细胞淋巴瘤（CLL / SLL）的标记物公开(公告)号：US20110236915A1
公开(公告)日：2011-09-29
申请号：US13155198
申请日：2011-06-07
CPC分类号： G01N33/57426 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA mRNA or protein.
摘要翻译： 已经令人惊奇地发现，在蛋白质和mRNA水平上的ZAP-70表达指示CLL / SLL患者的临床亚组。 特别地，高ZAP-70表达指示Ig-未突变的CLL / SLL。 提供了通过确定受试者是否过表达ZAP-70 mRNA mRNA或蛋白质来区分CLL / SLL的临床亚组的方法。
-
3.发明授权ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) 有权ZAP-70表达作为慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL / SLL）的标记物公开(公告)号：US07981610B2
公开(公告)日：2011-07-19
申请号：US11955322
申请日：2007-12-12
IPC分类号： C12Q1/68
CPC分类号： G01N33/57426 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein.
摘要翻译： 已经令人惊奇地发现，在蛋白质和mRNA水平上的ZAP-70表达指示CLL / SLL患者的临床亚组。 特别地，高ZAP-70表达指示Ig-未突变的CLL / SLL。 提供了通过确定受试者是否过表达ZAP-70 mRNA或蛋白质来区分CLL / SLL的临床亚组的方法。
-
4.发明申请ZAP-70 EXPRESSION AS A MARKER FOR CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) 有权ZAP-70表达作为慢性淋巴细胞淋巴瘤/小淋巴细胞淋巴瘤（CLL / SLL）的标记物公开(公告)号：US20080227741A1
公开(公告)日：2008-09-18
申请号：US11955322
申请日：2007-12-12
IPC分类号： A61K31/7088 , C12Q1/68 , A61P35/02
CPC分类号： G01N33/57426 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein.
摘要翻译： 已经令人惊奇地发现，在蛋白质和mRNA水平上的ZAP-70表达指示CLL / SLL患者的临床亚组。 特别地，高ZAP-70表达指示Ig-未突变的CLL / SLL。 提供了通过确定受试者是否过表达ZAP-70 mRNA或蛋白质来区分CLL / SLL的临床亚组的方法。
-
5.发明授权ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) 有权ZAP-70表达作为慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL / SLL）的标记物公开(公告)号：US08748114B2
公开(公告)日：2014-06-10
申请号：US13155198
申请日：2011-06-07
IPC分类号： G01N33/574
CPC分类号： G01N33/57426 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein.
摘要翻译： 已经令人惊奇地发现，在蛋白质和mRNA水平上的ZAP-70表达指示CLL / SLL患者的临床亚组。 特别地，高ZAP-70表达指示Ig-未突变的CLL / SLL。 提供了通过确定受试者是否过表达ZAP-70 mRNA或蛋白质来区分CLL / SLL的临床亚组的方法。
-
公开(公告)号：US20120316198A1
公开(公告)日：2012-12-13
申请号：US13513819
申请日：2010-12-03
IPC分类号： A61K31/341 , C07D405/12 , A61K31/4178 , C07D233/36 , A61K31/443 , C07D217/26 , A61K31/4725 , A61P35/00 , A61P9/00 , A61P19/02 , A61P31/00 , A61P25/28 , A61P7/02 , A61P9/10 , A61P17/00 , A61P29/00 , A61P27/02 , A61P37/00 , A61P31/12 , C07D307/75
CPC分类号： C07D307/73 , C07D307/75
摘要： Disclosed herein are novel hydrazone and diacyl hydrazine derivatives that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Also disclosed are hydrazone and diacyl hydrazine derivatives as potent and selective inhibitors of the p97 ATPase. These agents provide useful tools for the study of protein degradation and other processes involving p97. Methods of treating diseases or disorders for which p97 inhibition and/or ER stress induction is an effective treatment with certain hydrazone and diacyl hydrazine derivatives are also disclosed.
摘要翻译： 本文公开了新型腙和二酰基肼衍生物，其是内质网相关蛋白降解（ERAD）途径的抑制剂。 还公开了腙和二酰基肼衍生物作为p97 ATP酶的有效和选择性抑制剂。 这些试剂为研究蛋白质降解和涉及p97的其他过程提供了有用的工具。 还公开了治疗p97抑制和/或ER应激诱导对某些腙和二酰基肼衍生物有效治疗的疾病或病症的方法。
-
7.发明申请IMIDAZOLIDINONE COMPOUNDS, METHODS TO INHIBIT DEUBIQUITINATION AND METHODS OF TREATMENT 有权咪唑啉酮化合物，抑制免疫方法和治疗方法公开(公告)号：US20100286091A1
公开(公告)日：2010-11-11
申请号：US12669361
申请日：2008-07-18
申请人： Adrian Wiestner , William Trenkle , Qiuyan Wang , Yihong Ye , Helena Mora-Jensen
发明人： Adrian Wiestner , William Trenkle , Qiuyan Wang , Yihong Ye , Helena Mora-Jensen
IPC分类号： A61K31/69 , A61K31/4166 , C07D233/32 , A61P31/12
CPC分类号： A61K31/4178 , A61K31/4166
摘要： The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination.
摘要翻译： 本发明涉及咪唑烷酮化合物和咪唑啉酮化合物的药物组合物。 本发明的化合物用于治疗受试者的去泛素化相关病症并抑制p97相关的脱蛋白化的方法。
-
8.发明授权Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment 有权咪唑啉酮化合物，抑制去泛素化的方法和治疗方法公开(公告)号：US08637560B2
公开(公告)日：2014-01-28
申请号：US12669361
申请日：2008-07-18
申请人： William Trenkle , Adrian Wiestner , Qiuyan Wang , Yihong Ye , Helena Mora-Jensen
发明人： William Trenkle , Adrian Wiestner , Qiuyan Wang , Yihong Ye , Helena Mora-Jensen
IPC分类号： A61K31/4166 , C07D233/32
CPC分类号： A61K31/4178 , A61K31/4166
摘要： The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination.
摘要翻译： 本发明涉及咪唑烷酮化合物和咪唑啉酮化合物的药物组合物。 本发明的化合物用于治疗受试者的去泛素化相关病症并抑制p97相关的脱蛋白化的方法。
-
公开(公告)号：US08518968B2
公开(公告)日：2013-08-27
申请号：US13513819
申请日：2010-12-03
IPC分类号： A61K31/341 , A61K31/4178 , A61K31/443 , A61K31/4725 , C07D405/12 , C07D233/36 , C07D217/26 , C07D307/75
CPC分类号： C07D307/73 , C07D307/75
摘要： Disclosed herein are novel hydrazone and diacyl hydrazine derivatives that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Also disclosed are hydrazone and diacyl hydrazine derivatives as potent and selective inhibitors of the p97 ATPase. These agents provide useful tools for the study of protein degradation and other processes involving p97. Methods of treating diseases or disorders for which p97 inhibition and/or ER stress induction is an effective treatment with certain hydrazone and diacyl hydrazine derivatives are also disclosed.
摘要翻译： 本文公开了新型腙和二酰基肼衍生物，其是内质网相关蛋白降解（ERAD）途径的抑制剂。 还公开了腙和二酰基肼衍生物作为p97 ATP酶的有效和选择性抑制剂。 这些试剂为研究蛋白质降解和涉及p97的其他过程提供了有用的工具。 还公开了治疗p97抑制和/或ER应激诱导对某些腙和二酰基肼衍生物有效治疗的疾病或病症的方法。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.038 秒)
